nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

12.08.2018 | Original Article – Cancer Research

Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification

verfasst von: Tarek A. Bismar, Samar Hegazy, Zhaoyong Feng, Darryl Yu, Bryan Donnelly, Nallasivam Palanisamy, Bruce J. Trock

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To assess the prognostic value of ERG and PTEN protein expression as two of the most common genetic aberration in men with prostate cancer managed non-surgically by androgen deprivation therapy (ADT).

Materials and methods

463 tumor samples were assessed by double immunohistochemistry stains for ERG and PTEN and data correlated with clinical pathological features including, Gleason score, patients’ outcome and ADT.

Results

ERG expression and PTEN protein loss were present in 28.2% and 38% of total patients respectively. There was a significant interplay between ERG and PTEN expression with 21.8% PTEN negative tumors being ERG positive (p < 0.001). Both ERG and PTEN showed significant association with lethal disease in all patients and those treated with prior ADT representing castrate-resistant disease. However, only PTEN remained significant in multivariable proportional hazards regression analysis, when including Gleason score and patients’ age. Depending on patient’s subgroup, intact positive PTEN intensity showed better cancer-specific survival with HR ranging from 0.25 to 0.4 compared to tumors with loss of PTEN expression. Assessing combined marker status, patients with decreased PTEN intensity without ERG positivity showed the worst clinical outcome compared to those with no PTEN loss and no ERG expression, where they had best clinical outcome. Patients with ERG expression with or without PTEN loss showed intermediate risk in relation to lethal disease.

Conclusion

This study confirms a significant prognostic role for assessing ERG and PTEN in men with prostate cancer. It supports a role for utilizing combined ERG/PTEN status clinically and prospectively for stratifying PCa patients into different prognostic groups.

Abou-Ouf H, Zhao L, Bismar TA (2016) ERG expression in prostate cancer: biological relevance and clinical implication. J Cancer Res Clin Oncol 142(8):1781–1793. https://doi.org/10.1007/s00432-015-2096-x CrossRefPubMed

Ahearn TU, Pettersson A, Ebot EM, Gerke T, Graff RE, Morais CL, Hicks JL, Wilson KM, Rider JR, Sesso HD, Fiorentino M, Flavin R, Finn S, Giovannucci EL, Loda M, Stampfer MJ, De Marzo AM, Mucci LA, Lotan TL (2016) A prospective investigation of PTEN loss and ERG expression in lethal prostate cancer. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv346 CrossRefPubMed

Bismar TA, Yoshimoto M, Vollmer RT, Duan Q, Firszt M, Corcos J, Squire JA (2011) PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer. BJU Int 107 (3):477–485. https://doi.org/10.1111/j.1464-410X.2010.09470.x CrossRefPubMed

Bismar TA, Dolph M, Teng LH, Liu S, Donnelly B (2012) ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality. Eur J Cancer 48(4):538–546. https://doi.org/10.1016/j.ejca.2012.01.001 CrossRefPubMed

Dal Pra A, Lalonde E, Sykes J, Warde F, Ishkanian A, Meng A, Maloff C, Srigley J, Joshua AM, Petrovics G, van der Kwast T, Evans A, Milosevic M, Saad F, Collins C, Squire J, Lam W, Bismar TA, Boutros PC, Bristow RG (2013) TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. Clin Cancer Research 19(18):5202–5209. https://doi.org/10.1158/1078-0432.CCR-13-1049 CrossRef

Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, Hoshida Y, Mosquera JM, Pawitan Y, Lee C, Adami HO, Mucci LA, Kantoff PW, Andersson SO, Chinnaiyan AM, Johansson JE, Rubin MA (2007) TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26(31):4596–4599. https://doi.org/10.1038/sj.onc.1210237 CrossRef

Facher EA, Law JC (1998) PTEN and prostate cancer. J Med Genet 35(9):790CrossRef

Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496CrossRef

Guedes LB, Tosoian JJ, Hicks J, Ross AE, Lotan TL (2017) PTEN loss in Gleason score 3 + 4 = 7 prostate biopsies is associated with nonorgan confined disease at radical prostatectomy. J Urol 197(4):1054–1059. https://doi.org/10.1016/j.juro.2016.09.084 CrossRefPubMed

Hoogland AM, Jenster G, van Weerden WM, Trapman J, van der Kwast T, Roobol MJ, Schroder FH, Wildhagen MF, van Leenders GJ (2012) ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. Mod Pathol 25(3):471–479. https://doi.org/10.1038/modpathol.2011.176 CrossRefPubMed

Huang KC, Alshalalfa M, Hegazy SA, Dolph M, Donnelly B, Bismar TA (2014a) The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy. Cancer Biol Ther 15(9):1120–1128. https://doi.org/10.4161/cbt.29689 CrossRefPubMedPubMedCentral

Huang KC, Dolph M, Donnelly B, Bismar TA (2014b) ERG expression is associated with increased risk of biochemical relapse following radical prostatectomy in early onset prostate cancer. Clin Transl Oncol 16(11):973–979. https://doi.org/10.1007/s12094-014-1182-x CrossRefPubMed

Huang KC, Begin LR, Palanisamy N, Donnelly B, Bismar TA (2016) SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: implications for biomarker development. Urol Oncol 34(5):235 e231–210. https://doi.org/10.1016/j.urolonc.2015.11.015 CrossRef

Hyun T, Yam A, Pece S, Xie X, Zhang J, Miki T, Gutkind JS, Li W (2000) Loss of PTEN expression leading to high Akt activation in human multiple myelomas. Blood 96(10):3560–3568PubMed

Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, Adami HO (2004) Natural history of early, localized prostate cancer. Jama 291(22):2713–2719CrossRef

Lee SL, Yu D, Wang C, Saba R, Liu S, Trpkov K, Donnelly B, Bismar TA (2015) ERG expression in prostate needle biopsy: potential diagnostic and prognostic implications. Appl Immunohistochem Mol Morphol 23(7):499–505. https://doi.org/10.1097/PAI.0000000000000119 CrossRefPubMed

Liu S, Yoshimoto M, Trpkov K, Duan Q, Firszt M, Corcos J, Squire JA, Bismar TA (2011) Detection of ERG gene rearrangements and PTEN deletions in unsuspected prostate cancer of the transition zone. Cancer Biol Ther 11(6):562–566CrossRef

Lotan TL, Carvalho FL, Peskoe SB, Hicks JL, Good J, Fedor HL, Humphreys E, Han M, Platz EA, Squire JA, De Marzo AM, Berman DM (2015) PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy. Mod Pathol 28(1):128–137. https://doi.org/10.1038/modpathol.2014.85 CrossRefPubMed

Matsui S, Simon R, Qu P, Shaughnessy JD Jr, Barlogie B, Crowley J (2012) Developing and validating continuous genomic signatures in randomized clinical trials for predictive medicine. Clin Cancer Res 18(21):6065–6073. https://doi.org/10.1158/1078-0432.CCR-12-1206 CrossRefPubMedPubMedCentral

Reid AH, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, Clark J, Flohr P, Edwards S, Berney DM, Foster CS, Fletcher A, Gerald WL, Moller H, Reuter VE, Scardino PT, Cuzick J, de Bono JS, Cooper CS (2010) Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 102(4):678–684. https://doi.org/10.1038/sj.bjc.6605554 CrossRefPubMedPubMedCentral

Teng LH, Wang C, Begin LR, Dolph M, Yilmaz A, Trpkov K, Donnelly B, Bismar TA (2013a) ERG protein expression and gene rearrangements are present at lower rates in metastatic and locally advanced castration-resistant prostate cancer compared to localized disease. Urology 82(2):394–399. https://doi.org/10.1016/j.urology.2013.03.029 CrossRefPubMed

Teng LH, Wang C, Dolph M, Donnelly B, Bismar TA (2013b) ERG protein expression is of limited prognostic value in men with localized prostate cancer. ISRN Urol 2013:786545. https://doi.org/10.1155/2013/786545 CrossRefPubMedPubMedCentral

Tomlins SA, Palanisamy N, Siddiqui J, Chinnaiyan AM, Kunju LP (2012) Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies. Arch Pathol Lab Med 136(8):935–946. https://doi.org/10.5858/arpa.2011-0424-OA CrossRefPubMedPubMedCentral

Yoshimoto M, Joshua AM, Cunha IW, Coudry RA, Fonseca FP, Ludkovski O, Zielenska M, Soares FA, Squire JA (2008) Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol 21:1451CrossRef

Titel: Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification
verfasst von: Tarek A. Bismar
Samar Hegazy
Zhaoyong Feng
Darryl Yu
Bryan Donnelly
Nallasivam Palanisamy
Bruce J. Trock
Publikationsdatum: 12.08.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 11/2018
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-018-2730-5

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification

Abstract

Objectives

Materials and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Objectives

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2018

Locally advanced gastric cancer: total iodine uptake to predict the response of primary lesion to neoadjuvant chemotherapy

POLE gene hotspot mutations in advanced pancreatic cancer

Prognostic impact of hyperdiploidy in multiple myeloma patients with high-risk cytogenetics: a pilot study in China

Lentinan as an immunotherapeutic for treating lung cancer: a review of 12 years clinical studies in China

The functional role of exosome in hepatocellular carcinoma

The hippo pathway provides novel insights into lung cancer and mesothelioma treatment

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie